Back to Search
Start Over
RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis.
- Source :
- Oncology Letters; Jul2019, Vol. 18 Issue 1, p386-394, 9p
- Publication Year :
- 2019
-
Abstract
- Glioblastoma multiforme (GBM) is the most common and malignant type of glioma, with a poor prognosis for patients. The survival time of patients varies greatly due to the complexity of the human genome, which harbors diverse oncogenic drivers. In order to identify the specific driving factors, 325 glioma samples from the Chinese Glioma Genome Atlas (CGGA) database were analyzed in the present study. The level of RELB proto-oncogene, NF-κβ subunit (RELB) expression increased with the pathological grade progression of the gliomas, and higher expression levels were present in the mesenchymal subtype and isocitrate dehydrogenase 1 (IDH1) wild-type gliomas. This RELB expression pattern was identified in the CGGA database and observed in three large independent databases. In patients with GBM from the CGGA database, a higher RELB expression level was associated with a shorter survival time, a mesenchymal subtype and IDH1 wild-type gliomas. Kaplan-Meier survival analysis, survival nomograms and Cox analysis demonstrated an independent prognostic value for RELB expression. Moreover, biological function analysis indicated the association of RELB with the 'immune response', 'cell activation' and the 'apoptotic process'. In addition, RELB expression levels exhibited a negative correlation with the levels of microRNA (miR)-139-5p and miR-139-3p. The present study identified the pathological and biological roles of RELB in glioma and revealed its independent prognostic effect. These results suggested that RELB may be used as a prognostic biomarker and potential therapeutic target in glioma. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17921074
- Volume :
- 18
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Oncology Letters
- Publication Type :
- Academic Journal
- Accession number :
- 136809088
- Full Text :
- https://doi.org/10.3892/ol.2019.10296